RIYADH, Saudi Arabia, Oct. 24, 2025 –Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-powered drug discovery company, today announced that its founder and CEO, Dr. Alex Zhavoronkov, will be a featured speaker at the Fortune Global Forum in Riyadh, Saudi Arabia. Dr. Zhavoronkov will participate in two key panel discussions, where he will share his insights on the intersection of AI, longevity, and the future of healthcare. Leah Liu, Head of Capital Markets at Insilico Medicine, will also be attending the conference.
- Oct. 26, 5:00 PM, Main Stage: Living Better, Longer - A Social and Economic Imperative
- Oct. 27, 12:30 PM, Lunch Session: Hacking Our Defenses
The 2025 Fortune Global Forum, themed "The Great Convergence," will bring together CEOs and senior leaders from Fortune 500 companies, multinational corporations, and influential organizations across finance, energy, and technology. The forum will explore the transformative forces of artificial intelligence, geopolitical shifts, and changing demographics that are reshaping the global economy. Convening in Riyadh, Saudi Arabia, on October 26–27, 2025, this prestigious event will be held in the Kingdom for the first time—underscoring Saudi Arabia’s emergence as a leading hub for global business, trade, and innovation.
Dr. Zhavoronkov’s participation and insights align with his vision for “Pharmaceutical Superintelligence”—a fully autonomous AI platform capable of discovering and designing novel drugs for any disease without human intervention. This groundbreaking concept is detailed in two recent preprint papers from Insilico: one introducing TargetPro and Target Benchmark, the AI tools of Insilico’s biology superintelligence to de-risk research pipelines and prioritize targets for clinical investment; and another showcasing LEGION, a powerful AI-driven workflow of Insilico’s chemistry superintelligence that systematically explores chemical space.
"The Fortune Global Forum in Riyadh is a critical gathering of global leaders at a time when technological and economic forces are rapidly converging," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. "I am honored to share our vision for a future where generative AI can help us live better and longer. The discussions on longevity and AI in healthcare are not just theoretical; they are about tangible solutions to some of humanity's greatest challenges. At Insilico, we are proving that AI can accelerate the delivery of novel medicines to patients, and I look forward to exploring the social and economic imperatives of this revolution with fellow leaders."
Since establishing its generative AI and drug R&D center in Abu Dhabi in 2023, Insilico has advanced AI algorithm development and built strong industry collaborations across the Middle East. Notable achievements include publishing research in npj Aging and launching the AI-driven multimodal Precious GPT series for longevity research, as well as partnering with leading institutions to publish research in Nature Biotechnology on designing KRAS inhibitors using quantum-classical hybrid models.
Insilico was recognized with the Health Innovation Trailblazer Award from the UAE Genetic Diseases Society for its end-to-end AI-driven drug discovery platform, Pharma.AI. Most recently, Insilico launched a pilot project in the Middle East to discover the region’s first novel oncology drug candidate, leveraging its Pharma.AI platform and local resources to accelerate preclinical development.
Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D.While traditional early-stage drug discovery typically requires 2.5 to 4 years, Insilico has nominated 20 preclinical candidates with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
Since founding in 2014, Insilico has published over 200 peer-reviewed papers. Leveraging sustained scientific breakthroughs at the intersection of biotechnology, artificial intelligence, and automation, Insilico ranked Top 100 global corporate institutions in Nature Index's "2025 Research Leaders: global corporate institutions for biological sciences and natural sciences publications".
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, visit www.insilico.com.